Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 224

1.

Delay in schistosomiasis diagnosis and treatment: a multicenter cohortstudy in Italy.

Comelli A, Riccardi N, Canetti D, Spinicci M, Cenderello G, Magro P, Nicolini LA, Marchese V, Zammarchi L, Castelli F, Bartoloni A, Di Biagio A, Caligaris S, Gaiera G.

J Travel Med. 2019 Oct 16. pii: taz075. doi: 10.1093/jtm/taz075. [Epub ahead of print]

PMID:
31616948
2.

Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia.

Taramasso L, Di Biagio A, Riccardi N, Briano F, Di Filippo E, Comi L, Mora S, Giacomini M, Gori A, Maggiolo F.

PLoS One. 2019 Oct 11;14(10):e0223181. doi: 10.1371/journal.pone.0223181. eCollection 2019.

3.

Switching from efavirenz to rilpivirine improves sleep quality and self-perceived cognition but has no impact on neurocognitive performances: Results from a randomized controlled trial.

Lapadula G, Bernasconi DP, Bai F, Focà E, Di Biagio A, Bonora S, Castelli F, Squillace N, Bandera A, Monforte AD, Migliorino GM, Gori A; SWEAR Study Group.

AIDS. 2019 Sep 26. doi: 10.1097/QAD.0000000000002377. [Epub ahead of print]

PMID:
31567160
4.

A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study).

Mussini C, Roncaglia E, Borghi V, Rusconi S, Nozza S, Cattelan AM, Segala D, Bonfanti P, Di Biagio A, Barchi E, Focà E, Degli Antoni A, Bonora S, Francisci D, Limonta S, Antinori A, D'Ettorre G, Maggiolo F.

PLoS One. 2019 Sep 27;14(9):e0222650. doi: 10.1371/journal.pone.0222650. eCollection 2019.

5.

Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort.

Taramasso L, Lorenzini P, Di Biagio A, Lichtner M, Marchetti G, Rossotti R, Lapadula G, Cozzi-Lepri A, Vichi F, Antinori A, Bonora S, d'Arminio Monforte A; ICONA Foundation Study Group .

J Antimicrob Chemother. 2019 Nov 1;74(11):3295-3304. doi: 10.1093/jac/dkz353.

PMID:
31504633
6.

Smoking Habits in Human Immunodeficiency Virus-Infected People from Italy: A Cross-Sectional Analysis of the STOPSHIV Cohort.

De Socio GV, Maggi P, Ricci E, Orofino G, Squillace N, Menzaghi B, Madeddu G, Di Biagio A, Francisci D, Bonfanti P, Vichi F, Schiaroli E, Santoro C, Guastavigna M, dell'Omo M.

AIDS Res Hum Retroviruses. 2019 Oct 8. doi: 10.1089/AID.2019.0115. [Epub ahead of print]

PMID:
31502468
7.

Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA).

Taramasso L, Ricci E, Cascio A, Valsecchi L, Menzaghi B, Squillace N, Maggi P, De Socio GV, Dentone C, Madeddu G, Pellicanò GF, Calza L, Angioni G, Bonfanti P, Di Biagio A; CISAI Study Group.

AIDS Res Ther. 2019 Aug 26;16(1):21. doi: 10.1186/s12981-019-0236-0.

8.

The Ligurian HIV Network: How Medical Informatics Standards Can Help Clinical Research.

Giannini B, Mora S, Gazzarata R, Di Biagio A, Cenderello G, Dentone C, Setti M, Fenoglio D, Cassola G, Viscoli C, Giacomini M.

Stud Health Technol Inform. 2019 Aug 21;264:1666-1667. doi: 10.3233/SHTI190587.

PMID:
31438283
9.

Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients.

Ungaro R, Taramasso L, Bruzzone B, Vicenti I, Galli L, Borghi V, Francisci D, Pecorari M, Zoncada A, Callegaro AP, Paolini E, Monno L, Bonora S, Di Biagio A; ARCA Study Group.

Clin Microbiol Infect. 2019 Jul 25. pii: S1198-743X(19)30393-3. doi: 10.1016/j.cmi.2019.07.004. [Epub ahead of print] No abstract available.

PMID:
31352080
10.

SLAM Project - Second-Level Diagnostic Assessment: Multidisciplinary approach to HIV Patients.

Di Biagio A, Bonfanti P, Madeddu G, De Socio G, Maggi P, Vichi F, Martinelli C, Menzaghi B, Orofino G, Squillace N, Ricci E, Acone B, Quirino T; C.I.S.A.I. Group.

New Microbiol. 2019 Jul;42(3):150-155. Epub 2019 Jul 15.

11.

Clusterization of co-morbidities and multi-morbidities among persons living with HIV: a cross-sectional study.

Maggi P, Santoro CR, Nofri M, Ricci E, De Gennaro N, Bellacosa C, Schiaroli E, Orofino G, Menzaghi B, Di Biagio A, Squillace N, Francisci D, Vichi F, Molteni C, Bonfanti P, Gaeta GB, De Socio GV.

BMC Infect Dis. 2019 Jun 25;19(1):555. doi: 10.1186/s12879-019-4184-z.

12.

Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study.

Leone S, Lorenzini P, Cozzi-Lepri A, Orofino G, Bernacchia D, Castagna A, Menozzi M, Guaraldi G, Madeddu G, Di Biagio A, Puoti M, Gori A, d'Arminio Monforte A; ICONA Foundation Study Group.

Eur J Clin Microbiol Infect Dis. 2019 Oct;38(10):1857-1865. doi: 10.1007/s10096-019-03618-8. Epub 2019 Jun 22.

PMID:
31230205
13.

Statins and aspirin in the prevention of cardiovascular disease among HIV-positive patients between controversies and unmet needs: review of the literature and suggestions for a friendly use.

Maggi P, De Socio GV, Cicalini S, D'Abbraccio M, Dettorre G, Di Biagio A, Martinelli C, Nunnari G, Rusconi S, Sighinolfi L, Spagnuolo V, Squillace N.

AIDS Res Ther. 2019 May 24;16(1):11. doi: 10.1186/s12981-019-0226-2.

14.

Is it time to re-think the use of etravirine in patients with available genotypic resistance test?

Del Puente F, Riccardi N, Taramasso L, Borghetti A, D'Avino A, Irene Bonelli S, De Luca A, Zazzi M, Di Biagio A.

Infect Dis (Lond). 2019 Jun;51(6):452-455. doi: 10.1080/23744235.2019.1569257. Epub 2019 Apr 30. No abstract available.

PMID:
31035844
15.

Bloodstream infections in patients living with HIV in the modern cART era.

Taramasso L, Liggieri F, Cenderello G, Bovis F, Giannini B, Mesini A, Giacomini M, Cassola G, Viscoli C, Di Biagio A.

Sci Rep. 2019 Apr 1;9(1):5418. doi: 10.1038/s41598-019-41829-3.

16.

Missed opportunities to prevent mother-to-child transmission of HIV in Italy.

Di Biagio A, Taramasso L, Gustinetti G, Burastero G, Giacomet V, La Rovere D, Genovese O, Giaquinto C, Rampon O, Carloni I, Hyppolite TK, Palandri L, Bernardi S, Bruzzese E, Badolato R, Gabiano C, Chiappini E, De Martino M, Galli L; Italian Register for HIV Infection in Children.

HIV Med. 2019 May;20(5):330-336. doi: 10.1111/hiv.12728. Epub 2019 Mar 29.

PMID:
30924576
17.

Immunological profile of an infant treated with integrase inhibitor from the neonatal period.

Taramasso L, Dentone C, Tatarelli P, Bruzzone B, Marras F, De Maria A, Gotta C, Castagnola E, Filaci G, Viscoli C, Fenoglio D, Di Biagio A.

J Virus Erad. 2019 Jan 1;5(1):47-49. No abstract available.

18.

Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients.

Riccardi N, Del Puente F, Taramasso L, Di Biagio A.

J Int Assoc Provid AIDS Care. 2019 Jan-Dec;18:2325958218821657. doi: 10.1177/2325958218821657.

PMID:
30798670
19.

The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study.

Rossetti B, Gagliardini R, Sterrantino G, Colangeli V, Latini A, Colafigli M, Vignale F, Rusconi S, Di Biagio A, Orofino G, Mezzaroma I, Vullo V, Francisci D, Mastroianni C, Trezzi M, Canovari B, Lamonica S, Ciccullo A, Borghetti A, DʼArminio Monforte A, Di Giambenedetto S, De Luca A; for GUSTA trial study group.

J Acquir Immune Defic Syndr. 2019 May 1;81(1):e17-e21. doi: 10.1097/QAI.0000000000001986. No abstract available.

20.

The Management of Geriatric and Frail HIV Patients. A 2017 Update from the Italian Guidelines for the Use of Antiretroviral Agents and the Diagnostic Clinical Management of HIV-1 Infected Persons.

Guaraldi G, Marcotullio S, Maserati R, Gargiulo M, Milic J, Franconi I, Chirianni A, Andreoni M, Galli M, Lazzarin A, D'Arminio Monforte A, Di Perri G, Perno CF, Puoti M, Vella S, Di Biagio A, Maia L, Mussi C, Cesari M, Antinori A.

J Frailty Aging. 2019;8(1):10-16. doi: 10.14283/jfa.2018.42.

PMID:
30734825
21.

Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting.

d'Arminio Monforte A, Cozzi-Lepri A, Di Biagio A, Marchetti G, Lo Caputo S, Rusconi S, Gianotti N, Mazzotta V, Mazzarello G, Costantini A, Castagna A, Antinori A; ICONA Foundation Study Group.

J Antimicrob Chemother. 2019 May 1;74(5):1363-1367. doi: 10.1093/jac/dky566.

PMID:
30698801
22.

Evidence-based renewal of the Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons.

Antinori A, Di Biagio A, Marcotullio S, Sarmati L, Andreoni M, Angarano G, Chirianni A, d'Arminio Monforte A, Di Perri G, Galli M, Gianotti N, Girardi E, Gori A, Mussini C, Perno CF, Lazzarin A.

New Microbiol. 2018 Oct;41(4):247-255. Review.

23.

Determinants of patient and health care services delays for tuberculosis diagnosis in Italy: a cross-sectional observational study.

Peri AM, Bernasconi DP, Galizzi N, Matteelli A, Codecasa L, Giorgio V, Di Biagio A, Franzetti F, Cingolani A, Gori A, Lapadula G.

BMC Infect Dis. 2018 Dec 20;18(1):690. doi: 10.1186/s12879-018-3609-4.

24.

Treatment of hepatitis C virus genotype 4 in the DAA era.

Di Biagio A, Taramasso L, Cenderello G.

Virol J. 2018 Nov 22;15(1):180. doi: 10.1186/s12985-018-1094-4. Review.

25.

Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort.

Modica S, Rossetti B, Lombardi F, Lagi F, Maffeo M, D'Autilia R, Pecorari M, Vicenti I, Bruzzone B, Magnani G, Paolucci S, Francisci D, Penco G, Sacchini D, Zazzi M, De Luca A, Di Biagio A.

HIV Med. 2019 Feb;20(2):137-146. doi: 10.1111/hiv.12692. Epub 2018 Nov 21.

PMID:
30461149
26.

Rationale for an Association Between PD1 Checkpoint Inhibition and Therapeutic Vaccination Against HIV.

Filaci G, Fenoglio D, Taramasso L, Indiveri F, Di Biagio A.

Front Immunol. 2018 Oct 23;9:2447. doi: 10.3389/fimmu.2018.02447. eCollection 2018.

27.

Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients.

Dentone C, Di Biagio A, Cozzi Lepri A, Fenoglio D, Filaci G, Lichtner M, Carrara S, Giacometti A, Sighinolfi L, Marchetti G, Antinori A, D'arminio Monforte A; ICONA Foundation Study Group.

HIV Clin Trials. 2018 Aug;19(4):158-162. doi: 10.1080/15284336.2018.1488453. Epub 2018 Nov 13.

PMID:
30422095
28.

Successful recovery of associated interstitial nephritis and focal segmental glomerulosclerosis in patients with HCV and HIV treated with sofosbuvir and daclatasvir and revision of literature.

Mirabella M, Taramasso L, Nicolini LA, Russo R, Viscoli C, Di Biagio A.

Clin Nephrol Case Stud. 2018 Oct 26;6:31-35. doi: 10.5414/CNCS109221. eCollection 2018.

29.

Ibalizumab and Fostemsavir in the Management of Heavily Pre-Treated HIV-infected Patients.

Riccardi N, Berruti M, Del Puente F, Taramasso L, Di Biagio A.

Recent Pat Antiinfect Drug Discov. 2018;13(3):190-197. doi: 10.2174/1574891X13666181031120019. Review.

PMID:
30378502
30.

HCV elimination plan leads to significant benefits in managing liver-related diseases and hospital interventions: a regional simulation.

Cenderello G, Taramasso L, Marra D, Orcamo P, Pasa A, Di Biagio A.

Expert Rev Pharmacoecon Outcomes Res. 2019 Apr;19(2):189-193. doi: 10.1080/14737167.2019.1537124. Epub 2018 Oct 22.

PMID:
30321071
31.

How has the cost of antiretroviral therapy changed over the years? A database analysis in Italy.

Taramasso L, Demma F, Bitonti R, Ferrazin A, Giannini B, Giacomini M, Beltramini S, Sasso E, Viscoli C, Di Biagio A.

BMC Health Serv Res. 2018 Sep 6;18(1):691. doi: 10.1186/s12913-018-3507-x.

32.

The Italian registry of pulmonary non-tuberculous mycobacteria - IRENE: the study protocol.

Aliberti S, Codecasa LR, Gori A, Sotgiu G, Spotti M, Di Biagio A, Calcagno A, Nardini S, Assael BM, Tortoli E, Besozzi G, Ferrarese M, Matteelli A, Girardi E, De Lorenzo S, Seia M, Gramegna A, Del Prato B, Terranova L, Oriano M, Sverzellati N, Mirsaeidi M, Chalmers JD, Haworth CS, Loebinger MR, Aksamit T, Winthrop K, Ringshausen FC, Previdi G, Blasi F; IRENE Network.

Multidiscip Respir Med. 2018 Aug 9;13(Suppl 1):33. doi: 10.1186/s40248-018-0141-8. eCollection 2018.

33.

Modulation of the Natural Killer Cell Compartment during DAAs treatment in Interferon-naïve HCV patients: The type of DAA matters.

Nicolini LA, Dettori S, Bozzano F, Di Biagio A, De Maria A.

Immunol Lett. 2018 Nov;203:112-115. doi: 10.1016/j.imlet.2018.08.004. Epub 2018 Aug 23. No abstract available.

PMID:
30144471
34.

Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA).

Taramasso L, Tatarelli P, Ricci E, Madeddu G, Menzaghi B, Squillace N, De Socio GV, Martinelli C, Gulminetti R, Maggi P, Orofino G, Vichi F, Di Biagio A, Bonfanti P; CISAI Study Group.

BMC Infect Dis. 2018 Jul 31;18(1):357. doi: 10.1186/s12879-018-3268-5.

35.

Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study.

Gagliardini R, Ciccullo A, Borghetti A, Maggiolo F, Bartolozzi D, Borghi V, Pecorari M, Di Biagio A, Callegaro AP, Bruzzone B, Saladini F, Paolucci S, Maserati R, Zazzi M, Di Giambenedetto S, De Luca A; ARCA Study Group .

Open Forum Infect Dis. 2018 May 15;5(6):ofy113. doi: 10.1093/ofid/ofy113. eCollection 2018 Jun.

36.

Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA).

Rusconi S, Adorni F, Tau P, Borghi V, Pecorari M, Maserati R, Francisci D, Monno L, Punzi G, Meraviglia P, Paolucci S, Di Biagio A, Bruzzone B, Mancon A, Micheli V, Zazzi M; ARCA (Antiviral Response Cohort Analysis).

J Clin Virol. 2018 Aug;105:112-117. doi: 10.1016/j.jcv.2018.06.012. Epub 2018 Jun 21.

PMID:
29957545
37.

A Comprehensive Development Agenda on Tenofovir Alafenamide in Clinical Practice.

Di Biagio A, Riccardi N, Rusconi S, Guaraldi G, Borderi M, De Luca A, Gianotti N, Lo Caputo S, Maggi P, Maserati R, Maggiolo F.

AIDS Rev. 2018 Apr-Jun;20(2):75-82. Review.

PMID:
29938701
38.

Hepatitis B Virus Vaccination in HIV: Immunogenicity and Persistence of Seroprotection up to 7 Years Following a Primary Immunization Course.

Nicolini LA, Magne F, Signori A, Di Biagio A, Sticchi L, Paganino C, Durando P, Viscoli C.

AIDS Res Hum Retroviruses. 2018 Nov;34(11):922-928. doi: 10.1089/AID.2017.0070. Epub 2018 Aug 16.

PMID:
29926738
39.

First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison.

Taramasso L, Di Biagio A, Maggiolo F, Tavelli A, Lo Caputo S, Bonora S, Zaccarelli M, Caramello P, Costantini A, Viscoli C, d'Arminio Monforte A, Cozzi-Lepri A; Italian Cohort Naive Antiretrovirals (ICONA) Foundation Study Group.

HIV Med. 2018 May 30. doi: 10.1111/hiv.12628. [Epub ahead of print]

PMID:
29846042
40.

Managing the long surviving HIV patient: a proposal for a multidimensional first-level diagnostic assessment.

Borderi M, Angarano G, Antinori A, Chirianni A, Cinque P, D'Arminio Monforte A, Di Biagio A, Di Perri G, Galli M, Gori A, Lazzarin A, Mussini C, Perno CF, Quirino T, Rizzardini G, Calza L, Viale P, Acone B, Andreoni M.

New Microbiol. 2018 Apr;41(2):112-117.

41.

Hepatitis C virus direct acting antivirals impact on renal function in the first 4 weeks of treatment.

Taramasso L, Montanari L, Di Biagio A.

AIDS. 2018 Jun 1;32(9):1202-1203. doi: 10.1097/QAD.0000000000001804. No abstract available.

PMID:
29746321
42.

Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project.

Bagella P, De Socio GV, Ricci E, Menzaghi B, Martinelli C, Squillace N, Maggi P, Orofino G, Calza L, Carenzi L, Celesia BM, Penco G, Di Biagio A, Valsecchi L, Vichi F, Colombo V, Parruti G, Dentone C, Falasca K, Bonfanti P, Madeddu G; C.I.S.A.I. Study Group, Italy.

Infect Drug Resist. 2018 Apr 26;11:615-623. doi: 10.2147/IDR.S152090. eCollection 2018.

43.

Electronic Health Records: From the Management of Patients to the Research Use of Clinical Data.

Giannini B, Curtaz F, Del Puente F, Di Biagio A, Giacomini M.

Stud Health Technol Inform. 2018;247:246-250.

PMID:
29677960
44.

Hypertensive Versus HIV-infected Patients: Who Has the Greatest Target Organ Damage? Comparison of Carotid Plaque Prevalence, Intima Media Thickness and Renal Resistive Index in the Two Groups of Patients.

Taramasso L, Mirabella M, Cappadona F, Bonino B, Riccardi N, Cenderello G, De Socio GV, Viscoli C, Viazzi F, Di Biagio A.

Curr Hypertens Rev. 2018;14(1):48-55. doi: 10.2174/1573402114666180307145051.

PMID:
29521243
45.

Predictors of retention in care in HIV-infected patients in a large hospital cohort in Italy.

Prinapori R, Giannini B, Riccardi N, Bovis F, Giacomini M, Setti M, Viscoli C, Artioli S, Di Biagio A.

Epidemiol Infect. 2018 Apr;146(5):606-611. doi: 10.1017/S0950268817003107. Epub 2018 Feb 28.

PMID:
29486818
46.

Dolutegravir Plus Rilpivirine as a Switch Option in cART-Experienced Patients: 96-Week Data.

Capetti AF, Cossu MV, Sterrantino G, Barbarini G, Di Giambenedetto S, De Socio GV, Orofino G, Di Biagio A, Celesia BM, Rusconi S, Argenteri B, Rizzardini G.

Ann Pharmacother. 2018 Aug;52(8):740-746. doi: 10.1177/1060028018761600. Epub 2018 Feb 26.

PMID:
29482352
47.

From Liguria HIV Web to Liguria Infectious Diseases Network: How a Digital Platform Improved Doctors' Work and Patients' Care.

Giannini B, Riccardi N, Cenderello G, Di Biagio A, Dentone C, Giacomini M.

AIDS Res Hum Retroviruses. 2018 Mar;34(3):239-240. doi: 10.1089/aid.2017.0064. Epub 2018 Feb 21. No abstract available.

PMID:
29466022
48.

Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients.

Taramasso L, Di Biagio A, Bovis F, Nicolini LA, Antinori A, Milazzo L, Sollima S, Gubertini G, Niero F, Saracino A, Bruno R, Borghi V, Montagnani F, Cattelan A, Hasson H, Taliani G, D'Arminio Monforte A, Mastroianni C, Di Perri G, Bigoni S, Puoti M, Spinetti A, Gori A, Boffa N, Cacopardo B, Giacometti A, Parruti G, Vullo V, Chirianni A, Teti E, Pasquazzi C, Segala D, Andreoni M.

PLoS One. 2018 Feb 20;13(2):e0192627. doi: 10.1371/journal.pone.0192627. eCollection 2018.

49.

Time to change the single-centre approach to management of patients with tuberculosis: a novel network platform with automatic data import and data sharing.

Riccardi N, Giannini B, Borghesi ML, Taramasso L, Cattaneo E, Cenderello G, Toscanini F, Giacomini M, Pontali E, Cassola G, Viscoli C, Di Biagio A.

ERJ Open Res. 2018 Feb 2;4(1). pii: 00108-2017. doi: 10.1183/23120541.00108-2017. eCollection 2018 Jan.

50.

Use of quantitative ultrasound as bone mineral density evaluation in an Italian female population living with HIV: A real-life experience.

Vitiello P, Taramasso L, Ricci E, Maggi P, Martinelli C, Gabrielli C, Vittorio De Socio G, Di Cristo V, Rusconi S, Falasca K, Menzaghi B, Tebini A, Di Biagio A.

J Women Aging. 2019 Mar-Apr;31(2):176-188. doi: 10.1080/08952841.2018.1428100. Epub 2018 Jan 25.

PMID:
29369016

Supplemental Content

Loading ...
Support Center